Amendment--Hypertension Diagnostics, Inc. Signed LOI Merger Agreement with China Specialty International Limited.

Hypertension Diagnostics, Inc. (OTC: HDII) is pleased to announce that they have signed LOI Merger Agreement with China Specialty (Hong Kong) International Limited., It has more than 30 registered trademarks, and its business focuses on licensing, distribution authorization, investment in China.

Mr. Bo Long, the Chairman of China Specialty (Hong Kong) International Limited noted that, “We are looking forward to taking the Company public on the OTC Markets in the U.S. We believe this will further our goals to continue expanding our business in China and Asian countries.

The two companies are looking forward to signing the final Merger Agreement.

China Specialty (Hong Kong) International Limited

China Specialty International Limited is established in 2007 and its founder Mr. Bo Long has over 25 years of experience related to traditional condiments and fast-moving consumer goods (FMCG) production.  Between 2003 to 2013, as a Co-founder, Mr. Bo Long helped Guangzhou Texian Food Co., Ltd. (the brand “Xian Ge“  http://www.gztxfood.com) to achieve nearly 1 billion RMB of annual turnover from the start-up. Between 2006 to 2019, Mr. Bo Long had invested 50 million RMB in two Chinese food processing plants, through which he had accumulated rich investment and management experience in the whole industry chain of condiments and FMCG products.

China Specialty International Limited holds and maintains more than 30 registered trademarks which Mr. Bo Long’s business and production relates to. As a holding company, China Specialty International Limited focuses on brand licensing, distribution authorization and investment related to these registered brands and trademarks in provincial-level, city-level, country-level administrative regions in China.

Hypertension Diagnostics, Inc.

Hypertension Diagnostics, Inc (OTC: HDII), is a public company currently trading on the OTC Markets (HDII). HDII was originally incorporated in MN

*Safe Harbor Statement Information in this press release may contain ‘forward-looking statements.' Statements describing objectives or goals or the Company's future plans are also forward-looking statements and are subject to risks and uncertainties, including the financial performance of the Company and market valuations of its stock, which could cause actual results to differ materially from those anticipated. Forward-looking statements in this news release are made pursuant to the ‘Safe Harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to sales, acceptance of Hypertension Diagnostics, Inc’s products, increased levels of competition, changes, dependence on intellectual property rights and other risks detailed from time to time in Hypertension Diagnostics, Inc. periodic reports filed with the regulatory

authorities.SOURCE: Hypertension Diagnostics, Inc

Investor Information: [email protected]